Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells: Discriminating friend from foe through the recognition of prenyl pyrophosphate antigens

Immunological Reviews

Volumn 215, Issue 1, 2007, Pages 59-76

  Morita, Craig T ^a   Jin, Chenggang ^a   Sarikonda, Ghanashyam ^a   Wang, Hong ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

T cells; T cell receptors; Human; Isoprenoid pathways; Microbial immunity; Tumor immunity

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CD40 ANTIGEN; CELL SURFACE RECEPTOR; CHEMOKINE; CYTOKINE; HOMING RECEPTOR; PAMIDRONIC ACID; PHOSPHATE; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TOLL LIKE RECEPTOR; ZOLEDRONIC ACID;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; BONE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG POTENCY; HELPER CELL; HEMATOPOIESIS; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; INFECTION; INFLAMMATION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; LIGAND BINDING; LYMPH NODE; LYMPHOCYTE HOMING; LYMPHOID TISSUE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANTIGEN PRESENTATION; DIPHOSPHATES; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROTEIN ISOPRENYLATION; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS;

EID: 33846804360     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2006.00479.x     Document Type: Review

References (168)

1. Brenner MB, et al. Identification of a putative second T-cell receptor. Nature 1986;322:145-149.
2. Rast JP, Anderson MK, Strong SJ, Luer C, Litman RT, Litman GW. α, β, γ, and δ T cell antigen receptor genes arose early in vertebrate phylogeny. Immunity 1997;6:1-11.
3. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic nonpeptide antigens recognized by human γδ T cells. Nature 1995;375:155-158.
4. Spada FM, et al. Self recognition of CD1 by γδ T cells: implications for innate immunity. J Exp Med 2000;191:937-948.
5. Morita CT, Mariuzza RA, Brenner MB. Antigen recognition by human γδ T cells: pattern recognition by the adaptive immune system. Springer Semin Immunopathol 2000;22:191-218.
6. + human γδ T cells. J Immunol 1992;148:575-583.
7. Tanaka Y, et al. Nonpeptide ligands for human γδ T cells. Proc Natl Acad Sci USA 1994;91:8175-8179.
8. Constant P, et al. Stimulation of human γδ T cells by nonpeptidic mycobacterial ligands. Science 1994;264:267-270.
9. Rohmer M. Mevalonate-independent methylerythritol phosphate pathway for isoprenoid biosynthesis. Elucidation and distribution. Pure Appl Chem 2003;75:375-387.
10. Kuzuyama T. Mevalonate and nonmevalonate pathways for the biosynthesis of isoprene units. Biosci Biotechnol Biochem 2002;66:1619-1627.
11. Eisenreich W, Bacher A, Arigoni D, Rohdich F. Biosynthesis of isoprenoids via the non-mevalonate pathway. Cell Mol Life Sci 2004;61:1401-1426.
12. Puan K-J, Wang H, Dairi T, Kuzuyama T, Morita CT. fldA is an essential gene required in the 2-C-methyl-D-erythritol 4-phosphate pathway for isoprenoid biosynthesis. FEBS Lett 2005;579:3802-3806.
13. Morita CT, Lee HK, Leslie DS, Tanaka YT, Bukowski JF, Märker-Hermann E. Recognition of nonpeptide prenyl pyrophosphate antigens by human γδ T cells. Microbes Infect 1999;1:175-186.
14. Belmant C, et al. 3-formyl-1-butyl pyrophosphate a novel mycobacterial metabolite-activating human γδ T cells. J Biol Chem 1999;274:32079-32084.
15. Jomaa H, et al. Vγ9/Vδ2 T cell activation induced by bacterial low molecular mass compounds depends on the 1-deoxy-D-xylulose 5-phosphate pathway of isoprenoid biosynthesis. FEMS Immunol Med Microbiol 1999;25:371-378.
16. Altincicek B, et al. Human γδ T cells are activated by intermediates of the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid biosynthesis. J Immunol 2001;166:3655-3658.
17. Eberl M, et al. Accumulation of a potent γδ T-cell stimulator after deletion of the lytB gene in Escherichia coli. Immunology 2002;106:200-211.
18. Hintz M, et al. Identification of (E)-4-hydroxy-3-methyl-but-2- enyl pyrophosphate as a major activator for human γδ T cells in Escherichia coli. FEBS Lett 2001;509:317-322.
19. Eberl M, Hintz M, Reichenberg A, Kollas A-K, Wiesner J, Jomaa H. Microbial isoprenoid biosynthesis and human γδ T cell activation. FEBS Lett 2003;544:4-10.
20. Begley M, et al. The interplay between classical and alternative isoprenoid biosynthesis controls γδ T cell bioactivity of Listeria monocytogenes. FEBS Lett 2004;561:99-104.
21. Kuzuyama T, Takagi M, Takahashi S, Seto H. Cloning and characterization of 1-deoxy-D-xylulose 5-phosphate synthase from Streptomyces sp. strain CL190, which uses both the mevalonate and nonmevalonate pathways for isopentenyl diphosphate biosynthesis. J Bacteriol 2000;182:891-897.
22. Hamano Y, Dairi T, Yamamoto M, Kuzuyama T, Itoh N, Seto H. Growth-phase dependent expression of the mevalonate pathway in a terpenoid antibiotic-producing Streptomyces strain. Biosci Biotechnol Biochem 2002;66:808-819.
23. Munk ME, Gatrill AJ, Kaufmann SHE. Target cell lysis and IL-2 secretion by γ/δ T lymphocytes after activation with bacteria. J Immunol 1990;145:2434-2439.
24. + γ/δ T cells by group A, B and C but not group D or F streptococci. Clin Exp Immunol 1992;89:301-304.
25. Köhler S, et al. A plastid of probable green algal origin in Apicomplexan parasites. Science 1997;275:1485-1489.
26. Hecht S, et al. Studies on the nonmevalonate pathway to terpenes: the role of the GcpE (IspG) protein. Proc Natl Acad Sci USA 2001;98:14837- 14842.
27. Rohdich F, et al. Studies on the nonmevalonate terpene biosynthetic pathway: metabolic role of IspH (LytB) protein. Proc Natl Acad Sci USA 2002;99:1158-1163.
28. Reichenberg A, et al. Replacing the pyrophosphate group of HMB-PP by a diphosphonate function abrogates Its potential to activate human γδ T cells but does not lead to competitive antagonism. Bioorg Med Chem Lett 2003;13:1257-1260.
29. Bürk MR, Mori L, De Libero G. Human Vγ9-Vδ2 cells are stimulated in a cross-reactive fashion by a variety of phosphorylated metabolites. Eur J Immunol 1995;25:2052-2058.
30. Morita CT, Lee HK, Wang H, Li H, Mariuzza RA, Tanaka Y. Structural features of non-peptide prenyl pyrophosphates that determine their antigenicity for human γδ T cells. J Immunol 2001;167:36-41.
31. Tanaka Y, et al. Synthesis of pyrophosphate-containing compounds that stimulate Vγ2Vδ2 T cells: application to cancer immunotherapy. Med Chem 2006 (in press).
32. Belmant C, et al. A chemical basis for selective recognition of nonpeptide antigens by human γδ T cells. FASEB J 2000;14:1669-1670.
33. Espinosa E, et al. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human γδ T cells. J Biol Chem 2001;276:18337-18344.
34. Song Y, et al. Synthesis of chiral phosphoantigens and their activity in γδ T cell stimulation. Bioorg Med Chem Lett 2004;14:4471- 4477.
35. Morita CT, et al. Direct presentation of nonpeptide prenyl pyrophosphate antigens to human γδ T cells. Immunity 1995;3:495-507.
36. Zhang Y, et al. Structural studies of Vγ2Vδ2 T cell phosphoantigens. Chem Biol 2006;13:985-992.
37. Feurle J, et al. Escherichia coli produces phosphoantigens activating human γδ T cells. J Biol Chem 2002;277:148-154.
38. Hosking D. Pharmacological therapy of Paget's and other metabolic bone diseases. Bone 2006;38:S3-S7.
39. Sauty A, et al. Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 1996;18:133-139.
40. Berenson JR, et al. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 2001;7:478-485.
41. Tripathy D, Body JJ, Bergstrom B. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. Clin Ther 2004;26:1947-1959.
42. Perry CM, Figgitt DP. Zoledronic acid: a review of its use in patients with advanced cancer. Drugs 2004;64:1197-1211.
43. Boonen S, Laan RF, Barton IP, Watts NB. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005;16:1291-1298.
44. Russell RG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 2006;1068:367-401.
45. Riebeling C, Forsea AM, Raisova M, Orfanos CE, Geilen CC. The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br J Cancer 2002;87:366-371.
46. Rogers MJ, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-2978.
47. Kunzmann V, Bauer E, Wilhelm M. γ/δ T-cell stimulation by pamidronate. N Engl J Med 1999;340:737-738.
48. Das H, Wang L, Kamath A, Bukowski JF. Vγ2Vδ2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 2001;98:1616-1618.
49. Kato Y, Tanaka Y, Tanaka H, Yamashita S, Minato N. Requirement of species-specific interactions for the activation of human γδ T cells by pamidronate. J Immunol 2003;170:3608-3613.
50. Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minato N. Targeting of tumor cells for human γδ T cells by nonpeptide antigens. J Immunol 2001;167:5092-5098.
51. Kato Y, Tanaka Y, Hayashi M, Okawa K, Minato N. Involvement of CD166 in the activation of human γδ T cells by tumor cells sensitized with nonpeptide antigens. J Immunol 2006;177:877-884.
52. Dieli F, et al. Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003;102:2310-2311.
53. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;96:384-392.
54. Sanders JM, et al. Quantitative structure-activity relationships for γδ T cell -activation by bisphosphonates. J Med Chem 2004;47:375-384.
55. Gossman W, Oldfield E. Quantitative structure-activity relations for γδ T cell activation by phosphoantigens. J Med Chem 2002;45:4868-4874.
56. Sanders JM, et al. Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. J Med Chem 2005;48:2957-2963.
57. Hosfield DJ, et al. Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J Biol Chem 2004;279:8526-8529.
58. Kavanagh KL, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 2006;103:7829-7834.
59. Rondeau JM, et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 2006;1:267-273.
60. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197:163-168.
61. Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced γδ-T-cell proliferation and activation in vitro. J Bone Miner Res 2004;19:278-288.
62. Kamath AB, Wang L, Das H, Li L, Reinhold VN, Bukowski JF. Antigens in tea-beverage prime human Vγ2Vδ2 T cells in vitro and in vivo for memory and nonmemory antibacterial cytokine responses. Proc Natl Acad Sci USA 2003;100:6009-6014.
63. Bukowski JF, Morita CT, Brenner MB. Human γδ T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity 1999;11:57-65.
64. Thompson K, Rojas-Navea J, Rogers MJ. Alkylamines cause Vγ9Vδ2 T-cell activation and proliferation by inhibiting the mevalonate pathway. Blood 2006;107:651-654.
65. Das H, et al. MICA engagement by human Vγ2Vδ2 T cells enhances their antigen-dependent effector function. Immunity 2001;15:83-93.
66. Fisch P, et al. Recognition by human Vγ9/Vδ2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. Science 1990;250:1269- 1273.
67. Selin LK, Stewart S, Shen C, Mao HQ, Wilkins JA. Reactivity of γδ T cells induced by the tumour cell line RPMI 8226: functional heterogeneity of clonal populations and role of GroEL heat shock proteins. Scand J Immunol 1992;36:107-117.
68. Sicard H, Al Saati T, Delsol G, Fournié JJ. Synthetic phosphoantigens enhance human Vγ9Vδ2 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol Med 2001;7:711-722.
69. Li X, Zhang X, Zhang Y. Establishment of a novel culture system for specific expansion of human γδ T cell and study of its biological properties. Zhonghua Yi Xue Za Zhi 1997;77:111-114.
70. Bukowski JF, Morita CT, Tanaka Y, Bloom BR, Brenner MB, Band H. Vγ2Vδ2 TCR-dependent recognition of nonpeptide antigens and Daudi cells analyzed by TCR gene transfer. J Immunol 1995;154:998-1006.
71. Harwood HJ Jr, Alvarez IM, Noyes WD, Stacpoole PW. In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma. J Lipid Res 1991;32:1237-1252.
72. Scotet E, et al. Tumor recognition following Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 2005;22:71-80.
73. Bukowski JF, Morita CT, Band H, Brenner MB. Crucial role of TCRγ chain junctional region in prenyl pyrophosphate antigen recognition by γδ T cells. J Immunol 1998;161:286-293.
74. Miyagawa F, et al. Essential contribution of germline-encoded lysine residues in Jγ1.2 segment to the recognition of nonpeptide antigens by human γδ T cells. J Immunol 2001;167:6773-6779.
75. Davodeau F, et al. Close correlation between Daudi and mycobacterial antigen recognition by human γδ T cells and expression of V9JPC1γ/V2DJCδ-encoded T cell receptors. J Immunol 1993;151:1214-1223.
76. Yamashita S, Tanaka Y, Harazaki M, Mikami B, Minato N. Recognition mechanism of nonpeptide antigens by human γδ T cells. Int Immunol 2003;15:1301-1307.
77. Shin S, et al. Antigen recognition determinants of γδ T cell receptors. Science 2005;308:252-255.
78. Allison TJ, Winter CC, Fournié JJ, Bonneville M, Garboczi DN. Structure of a human γδ T-cell antigen receptor. Nature 2001;411:820-824.
79. Adams EJ, Chien YH, Garcia KC. Structure of a γδ T cell receptor in complex with the nonclassical MHC T22. Science 2005;308:227- 231.
80. Lang F, et al. Early activation of human Vγ9Vδ2 T cell broad cytotoxicity and TNF production by nonpeptidic mycobacterial ligands. J Immunol 1995;154:5986-5994.
81. Suhrbier A, Burrows SR, Fernan A, Lavin MF, Baxter γδ, Moss DJ. Peptide epitope induced apoptosis of human cytotoxic T lymphocytes. Implications for peripheral T cell deletion and peptide vaccination. J Immunol 1993;150:2169-2178.
82. + cytotoxic T lymphocytes is due to fratricide. J Immunol 1993;151:658-667; erratum submitted.
83. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human γδ T cells. Science 2005;309:264-268.
84. Thompson K, Rogers MJ, Coxon FP, Crockett JC. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006;69:1624-1632.
85. Wang H, et al. Conservation of nonpeptide antigen recognition by rhesus monkey Vγ2Vδ2 T cells. J Immunol 2003;170:3696-3706.
86. Parker CM, et al. Evidence for extrathymic changes in the T cell receptor γ/δ repertoire. J Exp Med 1990;171:1597-1612.
87. Morita CT, Parker CM, Brenner MB, Band H. T cell receptor usage and functional capabilities of human γδ T cells at birth. J Immunol 1994;153:3979-3988.
88. De Rosa SC, Andrus JP, Perfetto SP, Mantovani JJ, Herzenberg LA, Roederer M. Ontogeny of γδ T cells in humans. J Immunol 2004;172: 1637-1645.
89. Dieli F, et al. Differentiation of effector/memory Vδ2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med 2003;198:391-397.
90. + T cells during mycobacterial infections. Science 2002;295:2255-2258.
91. Lai X, et al. Immune biology of macaque lymphocyte populations during mycobacterial infection. Clin Exp Immunol 2003;133:182-192.
92. Hoft DF, Brown RM, Roodman ST. Bacille Calmette-Guérin vaccination enhances human γδ T cell responsiveness to mycobacteria suggestive of a memory-like phenotype. J Immunol 1998;161:1045-1054.
93. Glatzel A, Wesch D, Schiemann F, Brandt E, Janssen O, Kabelitz D. Patterns of chemokine receptor expression on peripheral blood γδ T lymphocytes: strong expression of CCR5 is a selective feature of Vδ2/Vγ9 γδ T cells. J Immunol 2002;168:4920-4929.
94. + T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. J Immunol 2002;168:1484-1489.
95. Jin C, Morita CT. Chemokine biology of NK cells and γδ T cells. In: Mosser B, Letts GL, Neote K, eds. Chemokine Biology - Basic Research and Clinical Applications. Vol. 1. Immunobiology of Chemokines. Basel: Birkhäuser, 2006;1:59-78.
96. Brandes M, et al. Flexible migration program regulates γδ T-cell involvement in humoral immunity. Blood 2003;102:3693-3701.
97. Barnes PF, Grisso CL, Abrams JS, Band H, Rea TH, Modlin RL. γδ T lymphocytes in human tuberculosis. J Infect Dis 1992;165:506-512.
98. Bertotto A, et al. Lymphocytes bearing the γδ T cell receptor in acute Brucella melitensis infection. Eur J Immunol 1993;23:1177-1180.
99. Sumida T, et al. Predominant expansion of Vγ9/Vδ2 T cells in a tularemia patient. Infect Immun 1992;60:2554-2558.
100. Hara T, et al. Predominant activation and expansion of Vγ9-bearing γδ T cells in vivo as well as in vitro in Salmonella infection. J Clin Invest 1992;90:204-210.
101. Caldwell CW, Everett ED, McDonald G, Yesus YW, Roland WE. Lymphocytosis of γ/δ T cells in human ehrlichiosis. Am J Clin Pathol 1995;103:761-766.
102. Perera MK, Carter R, Goonewardene R, Mendis KN. Transient increase in circulating γ/δ T cells during Plasmodium vivax malarial paroxysms. J Exp Med 1994;179:311-315.
103. Scalise F, et al. Lymphocytes bearing the γδ T-cell receptor in acute toxoplasmosis. Immunology 1992;76:668-670.
104. Kroca M, Tärnvik A, Sjöstedt A. The proportion of circulating γδ T cells increases after the first week of onset of tularaemia and remains elevated for more than a year. Clin Exp Immunol 2000;120:280- 284.
105. Morita CT, Verma S, Aparicio P, Martinez C, Spits H, Brenner MB. Functionally distinct subsets of human γ/δ T cells. Eur J Immunol 1991;21:2999-3007.
106. García VE, et al. Single cell cytokine analysis of γδ T cell responses to nonpeptide mycobacterial antigens. J Immunol 1997;159:1328-1335.
107. Cipriani B, et al. Activation of C-C b-chemokines in human peripheral blood γδ T cells by isopentenyl pyrophosphate and regulation by cytokines. Blood 2000;95:39-47.
108. Dieli F, et al. Granulysin-dependent killing of intracellular and extracellular Mycobacterium tuberculosis by Vγ9/Vδ2 T lymphocytes. J Infect Dis 2001;184:1082-1085.
109. Wang L, Kamath A, Das H, Li L, Bukowski JF. Antibacterial effect of human Vγ2Vδ2 T cells in vivo. J Clin Invest 2001;108:1349- 1357.
110. Komori HK, Meehan TF, Havran WL. Epithelial and mucosal γδ T cells. Curr Opin Immunol 2006;18:534-538.
111. Workalemahu G, Foerster M, Kroegel C. Expression and synthesis of fibroblast growth factor-9 in human γδ T-lymphocytes. Response to isopentenyl pyrophosphate and TGF-β1/IL-15. J Leukoc Biol 2004;75:657-663.
112. Workalemahu G, Foerster M, Kroegel C. Expression of metalloproteinase-7 (matrilysin) in human blood and bronchoalveolar gamma/delta T-lymphocytes. Selective upregulation by the soluble non-peptidic mycobacterial phosphoantigen (isopentenyl pyrophosphate). J Cell Physiol 2006;207:67-74.
113. Workalemahu G, Foerster M, Kroegel C, Braun RK. Human γδ-T lymphocytes express and synthesize connective tissue growth factor: effect of IL-15 and TGF-β1 and comparison with αβ-T lymphocytes. J Immunol 2003;170:153-157.
114. McClanahan J, Fukushima PI, Stetler-Stevenson M. Increased peripheral blood gamma delta T-cells in patients with lymphoid neoplasia: a diagnostic dilemma in flow cytometry. Cytometry 1999;38:280-285.
115. Street SE, et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and γδ T cells. J Exp Med 2004;199:879-884.
116. Girardi M, et al. Regulation of cutaneous malignancy by γδ T cells. Science 2001;294:605-609.
117. Malkovska V, Cigel FK, Armstrong N, Storer BE, Hong R. Antilymphoma activity of human γδ T-cells in mice with severe combined immune deficiency. Cancer Res 1992;52:5610-5616.
118. Chen J, Niu H, He W, Ba D. Antitumor activity of expanded human tumor-infiltrating γδ T lymphocytes. Int Arch Allergy Immunol 2001;125:256-263.
119. Zheng BJ, et al. Anti-tumor effects of human peripheral γδ T cells in a mouse tumor model. Int J Cancer 2001;92:421-425.
120. Kabelitz D, Wesch D, Pitters E, Zöller M. Characterization of tumor reactivity of human Vγ9Vδ2 γδ T cells in vitro and in SCID mice in vivo. J Immunol 2004;173:6767-6776.
121. Lozupone F, et al. Effect of human natural killer and γδ T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res 2004;64:378-385.
122. Otto M, et al. Combination immunotherapy with clinical-scale enriched human γδ T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. Clin Cancer Res 2005;11:8486-8491.
123. Borst J, et al. A T-cell receptor γ/CD3 complex found on cloned functional lymphocytes. Nature 1987;325:683-688.
124. Guo BL, Liu Z, Aldrich WA, Lopez RD. Innate anti-breast cancer immunity of apoptosis-resistant human γδ-T cells. Breast Cancer Res Treat 2005;93:169-175.
125. Corvaisier M, et al. Vγ2Vδ2 T cell response to colon carcinoma cells. J Immunol 2005;175:5481-5488.
126. Fisch P, et al. Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vγ9Vδ2 T cells in tumor immunity. Eur J Immunol 1997;27:3368-3379.
127. Mariani S, et al. Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 2005;19:664-670.
128. von Lilienfeld-Toal M, et al. Activated γδ T cells express the natural cytotoxicity receptor natural killer p44 and show cytotoxic activity against myeloma cells. Clin Exp Immunol 2006;144:528-533.
129. + γδ-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J Urol 2005;173:1552-1556.
130. Viey E, et al. Phosphostim-activated γδ T cells kill autologous metastatic renal cell carcinoma. J Immunol 2005;174:1338-1347.
131. Kobayashi H, Tanaka Y, Yagi J, Toma H, Uchiyama T. Gamma/delta T cells provide innate immunity against renal cell carcinoma. Cancer Immunol Immunother 2001;50:115-124.
132. Sato K, et al. Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 2005;116:94-99.
133. Bauer S, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-729.
134. Girlanda S, et al. MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells costimulates pamidronate-activated γδ lymphocytes. Cancer Res 2005;65:7502-7508.
135. Cosman D, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001;14:123-133.
136. Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 2002;168:671-679.
137. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T. Activation of Vγ9VδT cells by NKG2D. J Immunol 2005;175: 2144-2151.
138. Poccia F, et al. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive Vγ9Vδ2 T lymphocytes. J Immunol 1997;159:6009-6017.
139. Carena I, Shamshiev A, Donda A, Colonna M, De Libero G. Major histocompatibility complex class I molecules modulate activation threshold and early signaling of T cell antigen receptor-γ/δ stimulated by nonpeptidic ligands. J Exp Med 1997;186:1769-1774.
140. Wilhelm M, et al. γδ T cells for immune therapy of patients with lymphoid malignancies. Blood 2003;102:200-206.
141. Bennouna J, et al. Phase I clinical trial of Bromohydrin pyrophosphate, BrHPP (Phosphostim), a Vγ9Vδ2 T lymphocytes agonist in combination with low dose interleukin-2 in patients with solid tumors. J Clin Oncol 2005;23:Issue 16, Supplement, Abstract 2536.
142. Kobayashi H, et al. Safety profile and antitumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2006 (in press).
143. Sicard H, et al. In vivo immunomanipulation of Vγ9Vδ2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol 2005;175:5471-5480.
144. Tough DF, Sprent J. Lifespan of γ/δ T cells. J Exp Med 1998;187:357-365.
145. + T cells. J Exp Med 2005;202:907-912.
146. Dudley ME, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-854.
147. Dudley ME, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-2357.
148. + cells increase with age and limit the repertoire of human γδ T cells. Eur J Immunol 1994;24:1914-1918.
149. Colonna-Romano G, et al. Impairment of gamma/delta T lymphocytes in elderly: implications for immunosenescence. Exp Gerontol 2004;39:1439- 1446.
150. Re F, Poccia F, Donnini A, Bartozzi B, Bernardini G, Provinciali M. Skewed representation of functionally distinct populations of Vγ9Vδ2 T lymphocytes in aging. Exp Gerontol 2005;40:59-66.
151. Argentati K, et al. Numerical and functional alterations of circulating γδ T lymphocytes in aged people and centenarians. J Leukoc Biol 2002;72:65-71.
152. Li B, et al. Disease-specific changes in γδ T cell repertoire and function in patients with pulmonary tuberculosis. J Immunol 1996;157:4222-4229.
153. + γδ T-cell tolerance to foreign antigens of Toxoplasma gondii. Proc Natl Acad Sci USA 1996;93:5136-5140.
154. + antigen receptors are present in increased proportions in a fraction of patients with tuberculosis or with sarcoidosis. Am Rev Respir Dis 1993;148:1685-1690.
155. Ito M, Kojiro N, Ikeda T, Ito T, Funada J, Kokubu T. Increased proportions of peripheral blood γδ T cells in patients with pulmonary tuberculosis. Chest 1992;102:195-197.
156. Ueta C, Tsuyuguchi I, Kawasumi H, Takashima T, Toba H, Kishimoto S. Increase of γ/δ T cells in hospital workers who are in close contact with tuberculosis patients. Infect Immun 1994;62:5434-5441.
157. Dieli F, Sireci G, Di Sano C, Champagne E, Fournié J-J, Salerno JI. Predominance of Vγ9/Vδ2 T lymphocytes in the cerebrospinal fluid of children with tuberculous meningitis: reversal after chemotherapy. Mol Med 1999;5:301-312.
158. Modlin RL, et al. Lymphocytes bearing antigen-specific γδ T-cell receptors accumulate in human infectious disease lesions. Nature 1989;339:544-548.
159. Poquet Y, et al. Expansion of Vγ9Vδ2 T cells is triggered by Francisella tularensis-derived phosphoantigens in tularemia but not after tularemia vaccination. Infect Immun 1998;66:2107-2114.
160. Kroca M, Johansson A, Sjöstedt A, Tärnvik A. Vγ9Vδ2 T cells in human legionellosis. Clin Diagn Lab Immunol 2001;8:949-954.
161. Schneider T, et al. The number and proportion of Vγ9/Vδ2 T cells rise significantly in the peripheral blood of patients after the onset of acute Coxiella burnetii infection. Clin Infect Dis 1997;24:261- 264.
162. Raziuddin S, Mir NA, El-Awad ME-H, Telmesani AW, Al-Janadi M. γδ T lymphocytes and proinflammatory cytokines in bacterial meningitis. J Allergy Clin Immunol 1994;93:793-798.
163. Jouen-Beades F, et al. In vivo and in vitro activation and expansion of γδ T cells during Listeria monocytogenes infection in humans. Infect Immun 1997;65:4267-4272.
164. Ho M, Webster HK, Tongtawe P, Pattanapanyasat K, Weidanz WP. Increased γδ T cells in acute Plasmodium falciparum malaria. Immunol Lett 1990;25:139-142.
165. Roussilhon C, Agrapart M, Ballet J-J, Bensussan A. T lymphocytes bearing the γδ T cell receptor in patients with acute Plasmodium falciparum malaria. J Infect Dis 1990;162:283-285.
166. + γδ T cells after acute Plasmodium falciparum and Plasmodium vivax malaria. J Allergy Clin Immunol 1996;97:1387-1392.
167. Raziuddin S, Telmasani AW, El-Awad ME, Al-Amari O, Al-Janadi M. γδ T cells and the immune response in visceral leishmaniasis. Eur J Immunol 1992;22:1143-1148.
168. Russo DM, Armitage RJ, Barral NM, Barral A, Grabstein KH, Reed SG. Antigen-reactive γδ T cells in human leishmaniasis. J Immunol 1993;151:3712-3718.